Literature DB >> 16611918

E2 proteins from high- and low-risk human papillomavirus types differ in their ability to bind p53 and induce apoptotic cell death.

Joanna L Parish1, Anna Kowalczyk, Hsin-Tien Chen, Geraldine E Roeder, Richard Sessions, Malcolm Buckle, Kevin Gaston.   

Abstract

The E2 proteins from oncogenic (high-risk) human papillomaviruses (HPVs) can induce apoptotic cell death in both HPV-transformed and non-HPV-transformed cells. Here we show that the E2 proteins from HPV type 6 (HPV6) and HPV11, two nononcogenic (low-risk) HPV types, fail to induce apoptosis. Unlike the high-risk HPV16 E2 protein, these low-risk E2 proteins fail to bind p53 and fail to induce p53-dependent transcription activation. Interestingly, neither the ability of p53 to activate transcription nor the ability of p53 to bind DNA, are required for HPV16 E2-induced apoptosis in non-HPV-transformed cells. However, mutations that reduce the binding of the HPV16 E2 protein to p53 inhibit E2-induced apoptosis in non-HPV-transformed cells. In contrast, the interaction between HPV16 E2 and p53 is not required for this E2 protein to induce apoptosis in HPV-transformed cells. Thus, our data suggest that this high-risk HPV E2 protein induces apoptosis via two pathways. One pathway involves the binding of E2 to p53 and can operate in both HPV-transformed and non-HPV-transformed cells. The second pathway requires the binding of E2 to the viral genome and can only operate in HPV-transformed cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16611918      PMCID: PMC1472007          DOI: 10.1128/JVI.80.9.4580-4590.2006

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Interaction between the HPV-16 E2 transcriptional activator and p53.

Authors:  P Massimi; D Pim; C Bertoli; V Bouvard; L Banks
Journal:  Oncogene       Date:  1999-12-16       Impact factor: 9.867

2.  Disruption of the E1 and E2 reading frames of HPV 16 in cervical carcinoma is associated with poor prognosis.

Authors:  M Kalantari; F Karlsen; G Kristensen; R Holm; B Hagmar; B Johansson
Journal:  Int J Gynecol Pathol       Date:  1998-04       Impact factor: 2.762

3.  Recruitment of p300/CBP in p53-dependent signal pathways.

Authors:  M L Avantaggiati; V Ogryzko; K Gardner; A Giordano; A S Levine; K Kelly
Journal:  Cell       Date:  1997-06-27       Impact factor: 41.582

4.  Repression of the integrated papillomavirus E6/E7 promoter is required for growth suppression of cervical cancer cells.

Authors:  D A Francis; S I Schmid; P M Howley
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

5.  The human papillomavirus (HPV) 16 E2 protein induces apoptosis in the absence of other HPV proteins and via a p53-dependent pathway.

Authors:  K Webster; J Parish; M Pandya; P L Stern; A R Clarke; K Gaston
Journal:  J Biol Chem       Date:  2000-01-07       Impact factor: 5.157

6.  The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300.

Authors:  H Zimmermann; R Degenkolbe; H U Bernard; M J O'Connor
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

7.  The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300.

Authors:  D Patel; S M Huang; L A Baglia; D J McCance
Journal:  EMBO J       Date:  1999-09-15       Impact factor: 11.598

8.  Papillomavirus E2 induces p53-independent apoptosis in HeLa cells.

Authors:  C Desaintes; S Goyat; S Garbay; M Yaniv; F Thierry
Journal:  Oncogene       Date:  1999-08-12       Impact factor: 9.867

9.  Disruption of the human papillomavirus type 16 E2 gene protects cervical carcinoma cells from E2F-induced apoptosis.

Authors:  A M Sanchez-Perez; S Soriano; A R Clarke; K Gaston
Journal:  J Gen Virol       Date:  1997-11       Impact factor: 3.891

10.  Crystal structure of the E2 DNA-binding domain from human papillomavirus type 16: implications for its DNA binding-site selection mechanism.

Authors:  R S Hegde; E J Androphy
Journal:  J Mol Biol       Date:  1998-12-18       Impact factor: 5.469

View more
  29 in total

1.  Growth inhibition of HeLa cells is a conserved feature of high-risk human papillomavirus E8^E2C proteins and can also be achieved by an artificial repressor protein.

Authors:  Jasmin Fertey; José Hurst; Elke Straub; Astrid Schenker; Thomas Iftner; Frank Stubenrauch
Journal:  J Virol       Date:  2010-12-29       Impact factor: 5.103

2.  Primary human cervical carcinoma cells require human papillomavirus E6 and E7 expression for ongoing proliferation.

Authors:  Thomas G Magaldi; Laura L Almstead; Stefania Bellone; Edward G Prevatt; Alessandro D Santin; Daniel DiMaio
Journal:  Virology       Date:  2011-11-05       Impact factor: 3.616

3.  Human papillomavirus E7 repression in cervical carcinoma cells initiates a transcriptional cascade driven by the retinoblastoma family, resulting in senescence.

Authors:  Kimberly Johung; Edward C Goodwin; Daniel DiMaio
Journal:  J Virol       Date:  2006-12-20       Impact factor: 5.103

4.  Tumor suppressor or oncogene? A critical role of the human papillomavirus (HPV) E2 protein in cervical cancer progression.

Authors:  Sophie Bellanger; Chye Ling Tan; Yue Zhen Xue; Sébastien Teissier; Françoise Thierry
Journal:  Am J Cancer Res       Date:  2011-01-24       Impact factor: 6.166

5.  Modulation of apoptosis and immune signaling pathways by the Hantaan virus nucleocapsid protein.

Authors:  Steven J Ontiveros; Qianjun Li; Colleen B Jonsson
Journal:  Virology       Date:  2010-03-12       Impact factor: 3.616

Review 6.  Modulation of apoptosis by human papillomavirus (HPV) oncoproteins.

Authors:  T O Garnett; P J Duerksen-Hughes
Journal:  Arch Virol       Date:  2006-07-27       Impact factor: 2.574

7.  Expression of the HPV11 E2 gene in transgenic mice does not result in alterations of the phenotypic pattern.

Authors:  Kerstin Leykauf; Kirsten Kabsch; Nikolaus Gassler; Lutz Gissmann; Angel Alonso; Johannes Schenkel
Journal:  Transgenic Res       Date:  2007-08-16       Impact factor: 2.788

8.  HPV16 E2-mediated potentiation of NF-κB activation induced by TNF-α involves parallel activation of STAT3 with a reduction in E2-induced apoptosis.

Authors:  Devan Prabhavathy; Bandaru Niranjana Prabhakar; Devarajan Karunagaran
Journal:  Mol Cell Biochem       Date:  2014-05-16       Impact factor: 3.396

9.  Human papillomavirus type 16 E2 protein transcriptionally activates the promoter of a key cellular splicing factor, SF2/ASF.

Authors:  Sarah Mole; Steven G Milligan; Sheila V Graham
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

10.  RNA splicing factors regulated by HPV16 during cervical tumour progression.

Authors:  Sarah Mole; Melanie McFarlane; Thanaporn Chuen-Im; Steven G Milligan; David Millan; Sheila V Graham
Journal:  J Pathol       Date:  2009-11       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.